From the Journals

Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial

Phase 3 results show fenebrutinib matched OCREVUS on disability progression in PPMS

  • By

  • February 17, 2026

  • 3 min

Share

Roche's fenebrutinib, a Bruton’s tyrosine kinase inhibitor, has shown promising results in a phase 3 trial against OCREVUS for primary progressive multiple sclerosis (PPMS). The FENtrepid study indicated fenebrutinib was non-inferior in reducing disability progression, achieving separation in treatment effects by 24 weeks. Notably, upper limb function improvement was significant, as a key measure of independence. Safety profiles were comparable, with mild elevations in liver enzymes noted. Regulatory submissions for fenebrutinib are planned following upcoming study results.

Original Source(s)

Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial

Phase 3 results show fenebrutinib matched OCREVUS on disability progression in PPMS

  • February 17, 2026

  • 3 min

Related Content

High Dose Vitamin D May Reduce MS Activity

Vitamin D significantly reduced disease activity in clinically isolated syndrome and early relapsing-remitting multiple sclerosis in the D-Lay MS trial.

Can HIIT Improve Symptoms Among Patients with MS?

A recent study looked at the effects of high-intensity interval training (HIIT) in bone and lipid metabolism markers as well as neuromotor abilities in patients with multiple sclerosis.

Diagnosing, Treating, and Preventing Multiple Sclerosis: Marcus Institute Gold Standard Center

Marcus Neuroscience Institute, established at Boca Raton Regional Hospital, has been a leader in neurological research and advanced therapies for years, bringing a personalized approach to treatment

  • by

  • April 5, 2024

  • 12 min